Transforming growth factor-β (TGF-β) regulates a wide variety of biological processes through two types of Ser/Thr transmembrane receptors: the TGF-β type I receptor and the TGF-β type II receptor (TβRII). Upon ligand binding, TGF-β type I receptor activated by TβRII propagates signals to Smad proteins, which mediate the activation of TGF-β target genes. In this study, we identify ADAM12 (a disintegrin and metalloproteinase 12) as a component of the TGF-β signaling pathway that acts through association with TβRII. We found that ADAM12 functions by a mechanism independent of its protease activity to facilitate the activation of TGF-β signaling, including the phosphorylation of Smad2, association of Smad2 with Smad4, and transcriptional activation. Furthermore, ADAM12 induces the accumulation of TβRII in early endosomal vesicles and stabilizes the TβRII protein presumably by suppressing the association of TβRII with Smad7. These results define ADAM12 as a new partner of TβRII that facilitates its trafficking to early endosomes in which activation of the Smad pathway is initiated.
Skip Nav Destination
Article navigation
16 July 2007
Report|
July 09 2007
The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor
Azeddine Atfi,
Azeddine Atfi
1Institut National de la Santé et de la Recherche Medicale, Unite 673, Hôpital St-Antoine, 75571 Paris, France
Search for other works by this author on:
Emmanuelle Dumont,
Emmanuelle Dumont
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Search for other works by this author on:
Frédéric Colland,
Frédéric Colland
3Hybrigenics, 75014 Paris, France
Search for other works by this author on:
Dominique Bonnier,
Dominique Bonnier
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Search for other works by this author on:
Annie L'Helgoualc'h,
Annie L'Helgoualc'h
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Search for other works by this author on:
Céline Prunier,
Céline Prunier
1Institut National de la Santé et de la Recherche Medicale, Unite 673, Hôpital St-Antoine, 75571 Paris, France
Search for other works by this author on:
Nathalie Ferrand,
Nathalie Ferrand
1Institut National de la Santé et de la Recherche Medicale, Unite 673, Hôpital St-Antoine, 75571 Paris, France
Search for other works by this author on:
Bruno Clément,
Bruno Clément
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Search for other works by this author on:
Ulla M. Wewer,
Ulla M. Wewer
4Department of Biomedicine and Biotech Research and Innovation Centre, University of Copenhagen, DK-1017 Copenhagen, Denmark
Search for other works by this author on:
Nathalie Théret
Nathalie Théret
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Search for other works by this author on:
Azeddine Atfi
1Institut National de la Santé et de la Recherche Medicale, Unite 673, Hôpital St-Antoine, 75571 Paris, France
Emmanuelle Dumont
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Frédéric Colland
3Hybrigenics, 75014 Paris, France
Dominique Bonnier
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Annie L'Helgoualc'h
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Céline Prunier
1Institut National de la Santé et de la Recherche Medicale, Unite 673, Hôpital St-Antoine, 75571 Paris, France
Nathalie Ferrand
1Institut National de la Santé et de la Recherche Medicale, Unite 673, Hôpital St-Antoine, 75571 Paris, France
Bruno Clément
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Ulla M. Wewer
4Department of Biomedicine and Biotech Research and Innovation Centre, University of Copenhagen, DK-1017 Copenhagen, Denmark
Nathalie Théret
2Institut National de la Santé et de la Recherche Medicale, Unite 620, Institut Federatif de Recherche 140, Université de Rennes I, 35043 Rennes, France
Correspondence to Nathalie Théret: [email protected]
Abbreviations used in this paper: ADAM, a disintegrin and metalloproteinase; EEA1, early endosomal antigen 1; HSC, hepatic stellate cell; PAI-1, plasminogen activator inhibitor-1; RD, Rhabdomyosarcoma; SARA, Smad anchor for receptor activation; shRNA, short hairpin RNA; TβRII, TGF-β type II receptor.
Received:
December 08 2006
Accepted:
June 14 2007
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2007
J Cell Biol (2007) 178 (2): 201–208.
Article history
Received:
December 08 2006
Accepted:
June 14 2007
Citation
Azeddine Atfi, Emmanuelle Dumont, Frédéric Colland, Dominique Bonnier, Annie L'Helgoualc'h, Céline Prunier, Nathalie Ferrand, Bruno Clément, Ulla M. Wewer, Nathalie Théret; The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor . J Cell Biol 16 July 2007; 178 (2): 201–208. doi: https://doi.org/10.1083/jcb.200612046
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement